📗 Cite This Artifact
📖
amyloid-pathology
active
wiki page
Created: 2026-04-02T07:19:55
By: crosslink-migration
Quality:
50%
✓ SciDEX
ID: wiki-mechanisms-amyloid-pathology
📖 Wiki Page
mechanism758 wordssynced 2026-04-02
Amyloid Pathology
Overview
flowchart TD
Amyloid_Pathology["Amyloid Pathology"] -->|"biomarker for"| Alzheimer_S["Alzheimer'S"]
amyloid_pathology["amyloid pathology"] -->|"drives"| Alzheimer_s_Disease["Alzheimer's Disease"]
AMYLOID_PATHOLOGY["AMYLOID PATHOLOGY"] -->|"associated with"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
Amyloid_Pathology["Amyloid Pathology"] -->|"involved in"| Alzheimer_S_Disease["Alzheimer'S Disease"]
Amyloid_Pathology["Amyloid Pathology"] -->|"biomarker for"| Alzheimer_s_Disease["Alzheimer's Disease"]
Amyloid_Pathology["Amyloid Pathology"] -->|"associated with"| Tau_Pathology["Tau Pathology"]
Amyloid_Pathology["Amyloid Pathology"] -->|"interacts with"| Neuroinflammation["Neuroinflammation"]
Amyloid_pathology["Amyloid pathology"] -->|"contributes to"| Alzheimer_s_Disease["Alzheimer's Disease"]
amyloid_pathology["amyloid pathology"] -->|"interacts with"| mitochondrial_dysfunction["mitochondrial dysfunction"]
Ptau217["Ptau217"] -->|"biomarker for"| Amyloid_Pathology["Amyloid Pathology"]
ABETA42["ABETA42"] -->|"component of"| Amyloid_Pathology["Amyloid Pathology"]
ABETA40["ABETA40"] -->|"component of"| Amyloid_Pathology["Amyloid Pathology"]
APOE4["APOE4"] -->|"causes"| amyloid_pathology["amyloid pathology"]
APOE4["APOE4"] -->|"upregulates"| Amyloid_Pathology["Amyloid Pathology"]
style amyloid_pathology fill:#4fc3f7,stroke:#333,color:#000
...Amyloid Pathology
Overview
Mermaid diagram (expand to render)
Amyloid pathology refers to the accumulation and deposition of misfolded proteins in tissues and organs. In Alzheimer's disease, [amyloid-beta](/proteins/amyloid-beta) (Abeta) peptides aggregate to form plaques, which are considered a central pathological feature of the disease [1]. [@charidimou2015]
Amyloid-Beta
Normal Physiology
Amyloid-beta is a peptide derived from the [amyloid precursor protein](/entities/app-protein) (APP) through sequential proteolytic cleavage by [beta-secretase](/entities/bace1) (BACE) and [gamma-secretase](/entities/gamma-secretase) [2]. The amyloidogenic processing pathway generates Aβ peptides of varying lengths, with Aβ40 being the most abundant species and Aβ42 being more aggregation-prone due to two additional hydrophobic residues at the C-terminus [3]. [@weller2000]
Aggregation Process
The aggregation of Aβ follows a nucleation-dependent polymerization mechanism: [@jellinger2005]
- Monomeric Aβ → Oligomers → Protofibrils → Fibrils → Plaques [4]
- Soluble oligomers are considered more toxic than plaques [5]
- Different Aβ species: Aβ40, Aβ42, Aβ43 [3]
- The critical concentration for nucleation is lower for Aβ42 compared to Aβ40 [6]
Plaque Types
Core Amyloid Plaques
- Dense-core plaques
- Contain Aβ fibrils in cross-β sheet conformation [7]
- Surrounded by dystrophic neurites
- Associated with neuritic plaques in AD diagnosis [8]
Diffuse Plaques
- Non-fibrillar Aβ deposits
- Less well-defined borders
- May be earlier stage of plaque formation [9]
- Can be found in cognitively normal individuals [10]
Vascular Amyloid (CAA)
- Deposited in cerebral blood vessels
- Associated with hemorrhage risk [11]
- Perivascular clearance impaired [12]
- CAA affects ~80% of AD cases to some degree [13]
Pathogenic Mechanisms
Synaptic Toxicity
- Soluble Aβ oligomers disrupt synaptic function [14]
- Loss of [dendritic spines](/cell-types/dendritic-spines) [15]
- Impaired neurotransmitter release [16]
- Synaptic loss correlates strongly with cognitive decline [17]
Calcium Dysregulation
- Aβ forms membrane pores allowing calcium influx [18]
- Mitochondrial dysfunction from calcium overload [19]
- Cellular energy deficits and ATP depletion [20]
Neuroinflammation
- Microglial activation via pattern recognition receptors [21]
- Cytokine release (IL-1β, TNF-α, IL-6) [22]
- Chronic inflammatory response contributes to neurodegeneration [23]
- Trem2 variants affect microglial response to amyloid [24]
Tau Pathology
- Amyloid triggers [tau](/proteins/tau) pathology [25]
- Spread along neural networks [26]
- Correlation with cognitive decline [27]
- Amyloid-tau interaction is synergistic [28]
Structural Biology of Amyloid Fibrils
Cross-β Sheet Structure
Amyloid fibrils adopt a characteristic cross-β sheet quaternary structure where β-strands run perpendicular to the fibril axis [7]. This structure is stabilized by hydrogen bonds between backbone amide and carbonyl groups, as well as side-chain interactions. Different Aβ strains can adopt distinct conformations, potentially explaining phenotypic heterogeneity in AD [29]. [@shankar2008]
Polymorphism
Aβ fibrils exhibit structural polymorphism, with distinct morphologies observed in different individuals and brain regions [30]. This polymorphism may influence disease progression and therapeutic response [31]. [@spires2005]
Aggregation Kinetics
Nucleation and Elongation
The aggregation process follows sigmoidal kinetics with three phases: [@kamenetz2003]
Factors Affecting Aggregation
- Concentration: Higher Aβ concentration accelerates aggregation [35]
- pH: Optimal aggregation at physiological pH [36]
- Metal ions: Cu²⁺ and Zn²⁺ promote aggregation [37]
- Post-translational modifications: Oxidation, phosphorylation affect kinetics [38]
Therapeutic Approaches
Immunotherapies
- Aducanumab: Anti-Aβ antibody (withdrawn from market) [39]
- [Lecanemab](/entities/lecanemab): Anti-protofibril antibody (approved for early AD) [40]
- [Donanemab](/entities/donanemab): Anti-plaque antibody (approved for early AD) [41]
- Donanemab demonstrated significant plaque reduction in TRAILBLAZER-ALZ 2 trial [42]
Secretase Inhibitors
- BACE inhibitors: Failed due to adverse effects [43]
- Gamma-secretase modulators: In development [44]
Anti-Aggregation Strategies
- Small molecules to prevent aggregation [45]
- Peptide-based inhibitors [46]
- Chaperone proteins (Hsp70, Hsp90) [47]
Recent Research Updates (2024-2026)
This section highlights recent publications relevant to this mechanism. [@terry1991]
- [A novel Mediterranean diet-inspired supplement reduces hippocampal amyloid deposits and microglial activation through the modulation of the microbiota gut-brain axis in 5xFAD mice.](https://pubmed.ncbi.nlm.nih.gov/41527932/) (2026) - Gut Microbes
- [lncRNAs: key player in Aβ deposition.](https://pubmed.ncbi.nlm.nih.gov/41784271/) (2026) - RNA Biol
- [GPR3 in neuro-metabolic-immune-reproductive nexus - a potential therapeutic target for Multi-System diseases.](https://pubmed.ncbi.nlm.nih.gov/41574602/) (2026) - Ann Med
- [Engineering nanobodies for drug delivery systems in Alzheimer's disease.](https://pubmed.ncbi.nlm.nih.gov/41568664/) (2026) - Artif Cells Nanomed Biotechnol
- [Control analysis of deep brain stimulation and optogenetics for Alzheimer's disease under the computational cortex model.](https://pubmed.ncbi.nlm.nih.gov/41306192/) (2026) - Cogn Neurodyn
Additional evidence sources: [@arispe1993] [@wang1992] [@mattson1997] [@hickman2010] [@griffin1998] [@heppner2015] [@griciuc2013] [@musiek2015] [@braak2011] [@nelson2012] [@ittner2018] [@cohen2023] [@guo2023] [@riek2016] [@knowles2009] [@carulla2005] [@sengupta2023] [@lomakin1996] [@gursky2000] [@bush2002] [@crouch2009] [@sevigny2016] [@van2023] [@mintun2021] [@sims2023] [@bace2018] [@bales2021] [@lupi2008] [@soto1996] [@evans2006]
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- Amyloid Oligomers
- [Clinical Trials in AD](/clinical-trials/)
Pathway Diagram
The following diagram shows the key molecular relationships involving amyloid-pathology discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)
Related Entities
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-amyloid-pathology |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-bd5fecd9b5ef |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-amyloid-pathology'} |
| _schema_version | 1 |
📊 Evidence Profile
Foundational
Evidence Balance
+0%
Certainty
100%
Debates
0
Incoming
107
Outgoing
157
0 supporting
0 contradicting
0 neutral
🌍 Provenance Graph
1 nodes, 0 edges
No provenance edges found
This artifact has no version history yet.
Linked Artifacts (252)
Reference URLs
Embed this artifact
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
HTML iframe
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-amyloid-pathology?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
Markdown link
[amyloid-pathology](http://scidex.ai/artifact/wiki-mechanisms-amyloid-pathology)
Direct URL
http://scidex.ai/artifact/wiki-mechanisms-amyloid-pathology
Preview
🔄 Adjacent Artifacts
Recommended based on your interests
💬 Discussion
Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.